Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camizestrant PK in Hepatic Impairment
NCT05790304Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of camizestrant in breast cancer, sponsored by AstraZeneca. Primary endpoints: Maximum Observed Plasma Concentration at 5 days, Time to Reach Maximum Observed Plasma Concentration at 5 days and 6 more. Started Feb 2023; status: completed.
02
Drugs
camizestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05790304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05790304.